应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
MRK 默沙东
盘前交易 06-03 04:32:53 EDT
115.65
+0.48
+0.42%
盘前
115.13
-0.52
-0.45%
04:28 EDT
最高
116.78
最低
114.50
成交量
831.15万
今开
114.50
昨收
115.17
日振幅
1.98%
总市值
2,870亿
流通市值
2,870亿
总股本
24.82亿
成交额
9.62亿
换手率
0.33%
流通股本
24.82亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜默沙东盘中下跌3.01%，报115.17美元
行情直击 · 06-01 22:47
异动解读｜默沙东盘中下跌3.01%，报115.17美元
Adcendo Aps：双方公司保留各自化合物全部商业权利，涵盖单药及联合疗法
美股速递 · 05-26
Adcendo Aps：双方公司保留各自化合物全部商业权利，涵盖单药及联合疗法
Adcendo Aps与默沙东达成临床合作与供应协议，共同评估Adce-T02与Keytruda联合疗法
美股速递 · 05-26
Adcendo Aps与默沙东达成临床合作与供应协议，共同评估Adce-T02与Keytruda联合疗法
Adcendo Aps达成协议：公司将资助1B期临床试验，默沙东将提供帕博利珠单抗
美股速递 · 05-26
Adcendo Aps达成协议：公司将资助1B期临床试验，默沙东将提供帕博利珠单抗
默沙东K药联合Padcev获欧盟CHMP积极意见，用于治疗顺铂不耐受肌层浸润性膀胱癌
环球市场播报 · 05-22
默沙东K药联合Padcev获欧盟CHMP积极意见，用于治疗顺铂不耐受肌层浸润性膀胱癌
默沙东股价因癌症数据上涨，为何这家制药商不会仅依赖一款“王牌药物”？
老虎资讯综合 · 05-22
默沙东股价因癌症数据上涨，为何这家制药商不会仅依赖一款“王牌药物”？
默沙东(MRK)与科伦联合研发取得突破 肺癌新药临床效果亮眼
金吾财讯 · 05-22
默沙东(MRK)与科伦联合研发取得突破 肺癌新药临床效果亮眼
异动解读 | 肺癌联合疗法III期试验成功，默沙东盘中大涨5.01%
异动解读 · 05-22
异动解读 | 肺癌联合疗法III期试验成功，默沙东盘中大涨5.01%
默沙东癌症疗法获积极进展 市场关注度升温
投资观察 · 05-22
默沙东癌症疗法获积极进展 市场关注度升温
异动解读｜默沙东盘中上涨4.5%，TROP2 ADC子宫内膜癌III期试验达双重主要终点
行情直击 · 05-22
异动解读｜默沙东盘中上涨4.5%，TROP2 ADC子宫内膜癌III期试验达双重主要终点
默沙东肺癌联合疗法III期研究成功，肿瘤进展风险降低65%
环球市场播报 · 05-22
默沙东肺癌联合疗法III期研究成功，肿瘤进展风险降低65%
默沙东Keytruda®联合Padcev®获欧盟CHMP积极意见，用于顺铂不适切可切除肌层浸润性膀胱癌成人围手术期治疗
美股速递 · 05-22
默沙东Keytruda®联合Padcev®获欧盟CHMP积极意见，用于顺铂不适切可切除肌层浸润性膀胱癌成人围手术期治疗
合作方科伦药业肺癌联合疗法达成晚期试验目标，默沙东股价盘前大涨3.7%
美股速递 · 05-22
合作方科伦药业肺癌联合疗法达成晚期试验目标，默沙东股价盘前大涨3.7%
异动解读｜默沙东盘前上涨3.18%，TROP2 ADC子宫内膜癌III期试验达双重主要终点
行情直击 · 05-22
异动解读｜默沙东盘前上涨3.18%，TROP2 ADC子宫内膜癌III期试验达双重主要终点
异动解读｜默沙东盘后上涨3.11%，TROP2 ADC子宫内膜癌III期试验达主要终点
行情直击 · 05-22
异动解读｜默沙东盘后上涨3.11%，TROP2 ADC子宫内膜癌III期试验达主要终点
科伦博泰生物与默沙东联合疗法安全性概览：Sac-TMT联合帕博利珠单抗总体可控，与各组分已知安全性特征一致
美股速递 · 05-22
科伦博泰生物与默沙东联合疗法安全性概览：Sac-TMT联合帕博利珠单抗总体可控，与各组分已知安全性特征一致
港股异动 | 科伦博泰生物(06990)涨超5% 与默沙东合作的TROP2 ADC全球III期研究达成主要终点
智通财经 · 05-21
港股异动 | 科伦博泰生物(06990)涨超5% 与默沙东合作的TROP2 ADC全球III期研究达成主要终点
国家广告审查委员会就Bravecto Quantum剂量宣称问题 将默沙东动物保健部门提交FTC及FDA处理
美股速递 · 05-20
国家广告审查委员会就Bravecto Quantum剂量宣称问题 将默沙东动物保健部门提交FTC及FDA处理
世卫组织驻刚果代表：默沙东Ervebo是潜在可预防埃博拉病毒的疫苗之一
美股速递 · 05-19
世卫组织驻刚果代表：默沙东Ervebo是潜在可预防埃博拉病毒的疫苗之一
默沙东ADC癌症新药再下一城，子宫内膜癌III期研究大获成功
环球市场播报 · 05-19
默沙东ADC癌症新药再下一城，子宫内膜癌III期研究大获成功
加载更多
公司概况
公司名称：
默沙东
所属市场：
NYSE
上市日期：
--
主营业务：
默克制药公司于1970年在新泽西州注册成立。该公司是一家全球医疗保健公司，通过其处方药提供创新的健康解决方案，包括生物疗法、疫苗和动物保健产品。该公司的营运主要以产品为基础进行管理，包括两个经营分部：制药及动物保健国际。
发行价格：
--
{"stockData":{"symbol":"MRK","market":"US","secType":"STK","nameCN":"默沙东","latestPrice":115.65,"timestamp":1780430400000,"preClose":115.17,"halted":0,"volume":8311471,"hourTrading":{"tag":"盘前","latestPrice":115.13,"preClose":115.65,"latestTime":"04:28 EDT","volume":266,"amount":30885.31586,"timestamp":1780475303251,"change":-0.52,"changeRate":-0.004496,"amplitude":0.014343},"delay":0,"changeRate":0.004167752018754919,"floatShares":2482022536,"shares":2482022536,"eps":3.575809,"marketStatus":"盘前交易","change":0.48,"latestTime":"06-03 04:32:53 EDT","open":114.5,"high":116.7799,"low":114.5,"amount":962356220.05621,"amplitude":0.019796,"askPrice":116.09,"askSize":29,"bidPrice":115.1,"bidSize":43,"shortable":3,"etf":0,"ttmEps":3.575809,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780493400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":-745790400000,"exchange":"NYSE","adjPreClose":115.65,"dividendRate":0.0287,"preHourTrading":{"tag":"盘前","latestPrice":115.13,"preClose":115.65,"latestTime":"04:28 EDT","volume":266,"amount":30885.31586,"timestamp":1780475303251,"change":-0.52,"changeRate":-0.004496,"amplitude":0.014343},"postHourTrading":{"tag":"盘后","latestPrice":115.5,"preClose":115.65,"latestTime":"19:58 EDT","volume":482982,"amount":55857429.1132,"timestamp":1780444684601,"change":-0.15,"changeRate":-0.001297,"amplitude":0.003026},"volumeRatio":0.7924499918110904,"impliedVol":0.2803,"impliedVolPercentile":0.148},"requestUrl":"/m/hq/s/MRK","defaultTab":"news","newsList":[{"id":"1155510638","title":"异动解读｜默沙东盘中下跌3.01%，报115.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155510638","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155510638?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:47","pubTimestamp":1780325232,"startTime":"0","endTime":"0","summary":"6月1日，默沙东盘中下跌3.01%，报115.17美元/股，成交额2.15亿美元。默沙东所在的制药行业整体承压，个股中，礼来跌2.44%，强生跌1.56%，辉瑞跌2.39%，施贵宝跌3.53%，诺和诺德跌3.14%。默克制药公司是一家全球医疗保健公司，通过其处方药提供创新的健康解决方案，包括生物疗法、疫苗和动物保健产品，公司营运包括制药及动物保健国际两个经营分部。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172241710","title":"Adcendo Aps：双方公司保留各自化合物全部商业权利，涵盖单药及联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1172241710","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172241710?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:09","pubTimestamp":1779793787,"startTime":"0","endTime":"0","summary":"Adcendo Aps宣布，合作双方将各自保留其相关化合物的全部商业化权益，这些权益范围包括作为单一疗法使用，或与其他疗法进行联合应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1116320737.USD","LU1035773651.USD","SG9999001440.SGD","LU0868494617.USD","MRK","SG9999001176.SGD","SG9999014567.USD","LU2106854487.HKD","IE00BSNM7G36.USD","LU0320765489.SGD","LU0965509101.SGD","LU2491050154.USD","LU1291159041.SGD","BK4588","LU0432979614.USD","LU0238689110.USD","LU1934455194.USD","LU2125154935.USD","LU2357627491.SGD","LU2023250843.SGD","SG9999014575.USD","SG9999013999.USD","LU2125154778.USD","LU0106261372.USD","LU1934455277.USD","LU0234572021.USD","BK4559","LU0070302665.USD","LU1061106388.HKD","LU2361044949.HKD","LU1093756325.SGD","LU1974910355.USD","LU0208291251.USD","BK4533","LU1023059063.AUD","LU0868494708.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU0942090050.USD","LU1989772923.USD","IE00B1BXHZ80.USD","LU2491050071.SGD","LU0477156953.USD","LU1923622614.USD","LU1941712264.USD","LU0058720904.USD","SGXZ57979304.SGD","SG9999014559.SGD","LU1037948541.HKD","LU0130102774.USD","BK4516","LU1162221912.USD","BK4550","IE00BFTCPJ56.SGD","LU0122379950.USD","LU0265550946.USD","LU0203345920.USD","IE00BBT3K403.USD","LU1585245621.USD","BK4585","LU2324357040.USD","LU0266013472.USD","LU2125909247.SGD","LU2491049909.HKD","IE00BLSP4452.SGD","LU1989772840.SGD","LU0289739699.SGD","LU1917777945.USD","LU1057294990.SGD","LU0859254822.USD","LU0130517989.USD","LU1093756168.USD","IE00BJJMRZ35.SGD","LU1989771016.USD","SG9999015341.SGD","LU0985320562.USD","LU1571399168.USD","LU2023250504.SGD","LU1066053197.SGD","LU0098860793.USD","LU2361045086.USD","LU1066051225.USD","LU0203347892.USD","BK4534","LU1983299246.USD","LU2361044865.SGD","SG9999014542.SGD","IE000M9KFDE8.USD","LU0006306889.USD","SG9999002232.USD","LU0211331839.USD","SG9999001176.USD","LU1069347547.HKD","SG9999015358.SGD","LU1116320901.HKD","IE00B2B36J28.USD","LU2089984988.USD","LU2125909593.SGD","LU1929549753.HKD","LU0861579265.USD","LU0980610538.SGD","LU0965509283.SGD","LU0648001328.SGD","LU1699723380.USD","LU0965509010.AUD","SG9999002224.SGD","LU2461242641.AUD","LU1201861249.SGD","IE00B4R5TH58.HKD","LU1430594728.SGD","LU0265550359.USD","LU0320765646.SGD","BK4007","LU2468319806.SGD","IE00BLSP4239.USD","LU1934455863.HKD","LU1037948897.HKD","LU2433249047.HKD","LU2112291526.USD","IE0009355771.USD","LU1066051498.USD","LU1941712348.USD","IE00BN8TJ469.HKD","IE0002141913.USD","LU0965508806.USD","LU1066051811.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142473894","title":"Adcendo Aps与默沙东达成临床合作与供应协议，共同评估Adce-T02与Keytruda联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1142473894","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142473894?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:08","pubTimestamp":1779793708,"startTime":"0","endTime":"0","summary":"Adcendo Aps宣布与默沙东（Merck）达成一项临床合作与供应协议。双方将携手评估其候选药物Adce-T02与默沙东的抗PD-1疗法Keytruda（帕博利珠单抗）联合使用的潜力。\n此项合作旨在探索联合用药方案在特定适应症中的疗效与安全性。通过结合Adcendo的靶向疗法与默沙东已确立的免疫肿瘤药物，双方期望能开发出更具创新性的癌症治疗策略。协议的达成标志着Adcendo在推进其研发管线的战略布局上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965508806.USD","LU1066051498.USD","LU1585245621.USD","LU1699723380.USD","LU0208291251.USD","LU1116320901.HKD","LU0203347892.USD","LU1037948897.HKD","LU1061106388.HKD","LU1162221912.USD","LU0130102774.USD","LU1941712348.USD","BK4534","LU2491050154.USD","LU1929549753.HKD","BK4007","IE0002141913.USD","BK4559","LU1035773651.USD","LU2461242641.AUD","IE00BLSP4452.SGD","LU0965509010.AUD","SG9999001176.SGD","LU1989772923.USD","SG9999014575.USD","IE00B4R5TH58.HKD","LU0942090050.USD","LU2023250843.SGD","IE00BJT1NW94.SGD","SG9999015341.SGD","LU1201861249.SGD","LU1023059063.AUD","LU0859254822.USD","LU0238689110.USD","IE000M9KFDE8.USD","LU1934455863.HKD","LU1989771016.USD","SG9999002232.USD","BK4516","LU1989772840.SGD","LU2361044949.HKD","LU0965509101.SGD","LU1291159041.SGD","LU1116320737.USD","SG9999002224.SGD","LU0058720904.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU0203345920.USD","SG9999014559.SGD","LU0432979614.USD","BK4533","LU1066053197.SGD","LU0648001328.SGD","LU2433249047.HKD","LU2491049909.HKD","LU0234572021.USD","LU2106854487.HKD","IE00B2B36J28.USD","LU2361044865.SGD","SG9999014542.SGD","LU1941712264.USD","LU2357627491.SGD","LU1983299246.USD","LU0985320562.USD","IE00BSNM7G36.USD","LU2125909593.SGD","LU1923622614.USD","LU0211331839.USD","LU1934455194.USD","LU2491050071.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU0130517989.USD","LU0289739699.SGD","LU0265550359.USD","LU0106261372.USD","LU1066051811.HKD","LU0266013472.USD","IE00BJJMRZ35.SGD","LU0006306889.USD","IE00BLSP4239.USD","LU2324357040.USD","LU0098860793.USD","LU2361045086.USD","SG9999014567.USD","IE00BBT3K403.USD","LU0070302665.USD","BK4585","LU0861579265.USD","IE00B1BXHZ80.USD","LU0868494617.USD","LU0320765489.SGD","SG9999015358.SGD","LU2112291526.USD","IE00BN8TJ469.HKD","LU1934455277.USD","LU1571399168.USD","LU2125154778.USD","LU1430594728.SGD","LU2089984988.USD","LU0477156953.USD","LU2125909247.SGD","BK4550","LU0122379950.USD","LU0965509283.SGD","LU2125154935.USD","LU1066051225.USD","MRK","LU1974910355.USD","LU1069347547.HKD","LU2023250504.SGD","LU0320765646.SGD","LU1917777945.USD","LU0868494708.USD","LU1093756325.SGD","LU1037948541.HKD","LU0980610538.SGD","LU2360032135.SGD","LU1093756168.USD","IE0009355771.USD","LU1057294990.SGD","SG9999001176.USD","LU0265550946.USD","LU2468319806.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193611796","title":"Adcendo Aps达成协议：公司将资助1B期临床试验，默沙东将提供帕博利珠单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=1193611796","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193611796?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:08","pubTimestamp":1779793701,"startTime":"0","endTime":"0","summary":"根据一项新达成的协议，Adcendo Aps公司将负责资助一项1B期临床试验，而默沙东将为此项试验提供其药物帕博利珠单抗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2433249047.HKD","LU1066051225.USD","IE00B2B36J28.USD","LU0211331839.USD","BK4007","LU0980610538.SGD","LU1066051811.HKD","LU1093756168.USD","LU1066051498.USD","BK4585","MRK","IE00B4R5TH58.HKD","LU1699723380.USD","SG9999014575.USD","LU0006306889.USD","LU2125909593.SGD","LU2461242641.AUD","LU1989771016.USD","LU1069347547.HKD","LU1037948541.HKD","LU1941712348.USD","SG9999002232.USD","LU0432979614.USD","SG9999013999.USD","LU1162221912.USD","SGXZ57979304.SGD","LU0965509010.AUD","LU0130102774.USD","LU0203345920.USD","LU1093756325.SGD","LU0098860793.USD","LU2324357040.USD","LU1291159041.SGD","LU0208291251.USD","LU1116320737.USD","LU2089984988.USD","LU0265550359.USD","LU0058720904.USD","LU1037948897.HKD","LU1066053197.SGD","LU1934455277.USD","SG9999001440.SGD","LU0106261372.USD","LU2360032135.SGD","LU2361044865.SGD","LU0122379950.USD","LU2357627491.SGD","LU1571399168.USD","IE0002141913.USD","LU0265550946.USD","LU0320765646.SGD","LU2491050071.SGD","LU0942090050.USD","LU0238689110.USD","LU1989772923.USD","IE00BFTCPJ56.SGD","LU2491049909.HKD","LU0965508806.USD","SG9999014567.USD","SG9999001176.SGD","LU0070302665.USD","SG9999015358.SGD","BK4588","SG9999002224.SGD","LU2125909247.SGD","LU1201861249.SGD","IE00BSNM7G36.USD","LU2106854487.HKD","IE000M9KFDE8.USD","SG9999001176.USD","LU1023059063.AUD","LU2361045086.USD","BK4550","LU1989772840.SGD","LU0130517989.USD","LU0320765489.SGD","LU0289739699.SGD","LU0203347892.USD","LU1035773651.USD","LU2361044949.HKD","LU0965509283.SGD","LU0965509101.SGD","LU1061106388.HKD","LU1057294990.SGD","LU1934455863.HKD","LU0861579265.USD","IE00B1BXHZ80.USD","LU0859254822.USD","IE00BLSP4239.USD","BK4533","LU0985320562.USD","LU2125154935.USD","LU1430594728.SGD","LU0477156953.USD","LU1983299246.USD","LU2125154778.USD","IE00BJJMRZ35.SGD","SG9999014559.SGD","IE00BJT1NW94.SGD","BK4534","BK4559","LU0868494708.USD","LU1917777945.USD","LU2023250504.SGD","LU0266013472.USD","LU1934455194.USD","LU0868494617.USD","LU1941712264.USD","IE00BN8TJ469.HKD","BK4516","LU2112291526.USD","SG9999014542.SGD","LU1585245621.USD","LU0648001328.SGD","LU1116320901.HKD","SG9999015341.SGD","LU2023250843.SGD","IE00BBT3K403.USD","IE0009355771.USD","LU1923622614.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU2491050154.USD","LU1974910355.USD","LU2468319806.SGD","LU1929549753.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637343626","title":"默沙东K药联合Padcev获欧盟CHMP积极意见，用于治疗顺铂不耐受肌层浸润性膀胱癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2637343626","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637343626?lang=zh_cn&edition=full","pubTime":"2026-05-22 23:28","pubTimestamp":1779463680,"startTime":"0","endTime":"0","summary":"默沙东于5月22日宣布，欧洲药品管理局人用药品委员会已采纳积极意见，推荐批准KEYTRUDA联合Padcev用于治疗顺铂不耐受的可切除肌层浸润性膀胱癌成人患者，作为新辅助治疗并在根治性膀胱切除术后继续作为辅助治疗。该试验在顺铂不耐受或拒绝接受含顺铂化疗的MIBC患者中，比较了围手术期K药联合Padcev治疗与单纯手术的效果。欧洲委员会预计将在2026年第三季度前做出最终审批决定。目前该联合疗法已在美国获得批准用于相同适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyuwef7534467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1069347547.HKD","MRK","LU2106854487.HKD","LU1974910355.USD","IE00BLSP4239.USD","LU0980610538.SGD","LU0320765489.SGD","LU0006306889.USD","LU0122379950.USD","LU1093756168.USD","LU2125154778.USD","LU1699723380.USD","LU0432979614.USD","LU0130102774.USD","LU2361044949.HKD","LU1162221912.USD","LU1066051498.USD","LU0965509283.SGD","LU0211331839.USD","LU1934455277.USD","LU0477156953.USD","SG9999014567.USD","LU1923622614.USD","LU1430594728.SGD","LU1917777945.USD","LU0942090050.USD","BK4516","LU1571399168.USD","LU2491050071.SGD","LU2361045086.USD","LU0868494617.USD","LU2360032135.SGD","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","IE00BN8TJ469.HKD","BK4588","SG9999014559.SGD","BK4559","LU0106261372.USD","BK4007","LU0203347892.USD","LU1116320901.HKD","LU0070302665.USD","BK4533","LU0985320562.USD","LU0058720904.USD","LU0861579265.USD","LU2125154935.USD","IE00BLSP4452.SGD","LU0868494708.USD","SG9999002232.USD","LU1035773651.USD","LU1066051225.USD","LU0208291251.USD","BK4550","LU1941712348.USD","SGXZ57979304.SGD","SG9999015358.SGD","LU2089984988.USD","LU1983299246.USD","SG9999013999.USD","IE00BJT1NW94.SGD","LU1989772923.USD","LU1066051811.HKD","LU2023250843.SGD","LU1929549753.HKD","LU0265550359.USD","LU0234572021.USD","LU0289739699.SGD","LU1941712264.USD","LU1057294990.SGD","LU0203345920.USD","LU1037948897.HKD","BK4585","SG9999014575.USD","LU2361044865.SGD","LU0859254822.USD","LU2023250504.SGD","SG9999015341.SGD","LU2125909247.SGD","SG9999002224.SGD","LU2461242641.AUD","LU0266013472.USD","IE00BBT3K403.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU1037948541.HKD","SG9999001176.SGD","LU1291159041.SGD","LU1934455863.HKD","IE0009355771.USD","LU1116320737.USD","LU1093756325.SGD","BK4534","LU2357627491.SGD","IE000M9KFDE8.USD","LU0265550946.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU2491049909.HKD","LU0965509010.AUD","LU1061106388.HKD","LU2125909593.SGD","IE00B1BXHZ80.USD","LU0098860793.USD","SG9999014542.SGD","LU0648001328.SGD","LU0965509101.SGD","IE0002141913.USD","LU0238689110.USD","LU1201861249.SGD","LU1585245621.USD","IE00B4R5TH58.HKD","LU0320765646.SGD","LU1989771016.USD","LU2112291526.USD","LU1989772840.SGD","LU0965508806.USD","LU2468319806.SGD","LU2491050154.USD","LU2433249047.HKD","LU0130517989.USD","LU2324357040.USD","SG9999001176.USD","LU1934455194.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125632815","title":"默沙东股价因癌症数据上涨，为何这家制药商不会仅依赖一款“王牌药物”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1125632815","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125632815?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:57","pubTimestamp":1779461871,"startTime":"0","endTime":"0","summary":"默沙东正试图缓解2028年即将到来的冲击，届时Keytruda的核心专利保护将开始到期。作为肿瘤治疗领域公认的“神药”，Keytruda是有史以来销量最高的药物之一，因此其失去市场独占权将对公司构成重大不利影响。2022年，默沙东与这家中国药企达成独家授权协议，共同建立用于癌症治疗的ADC产品组合。周五股价上涨还受到监管层面积极进展的进一步推动。","market":"us","thumbnail":"https://community-static.tradeup.com/news/46fe1aebdcc6399ee66a93a44835bba6","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/46fe1aebdcc6399ee66a93a44835bba6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"默沙东股价因癌症数据上涨，为何这家制药商不会仅依赖一款“王牌药物”？","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637531064","title":"默沙东(MRK)与科伦联合研发取得突破 肺癌新药临床效果亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2637531064","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637531064?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:14","pubTimestamp":1779459290,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦生物周四披露重要临床进展，企业与默沙东合作研发的抗体药物偶联物，相关疗法在晚期肺癌临床试验中，疗效表现超越常规抗 PD-1 治疗方案。公开试验摘要显示，默沙东 2022 年取得大中华区以外权益的 sac-TMT，可显著降低 65% 疾病进展与死亡风险，数据具备统计学价值。安全性层面两组差异明显，联合用药重度不良反应发生率为 55%，单药组仅 31%。两类药物停药相关不良反应占比分别为 4% 与 5%，单药停药比例同样为 5%。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","LU1066051225.USD","LU2461242641.AUD","LU1983299246.USD","LU0648001328.SGD","BK4516","LU1069347547.HKD","LU2360032135.SGD","SG9999014559.SGD","LU1989771016.USD","LU2023250504.SGD","LU2125154935.USD","LU0477156953.USD","BK4550","LU0985320562.USD","SG9999002224.SGD","LU2106854487.HKD","LU1989772840.SGD","LU1699723380.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU2089984988.USD","SG9999015358.SGD","IE000M9KFDE8.USD","LU0130102774.USD","BK4007","BK4533","LU1291159041.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU1035773651.USD","LU2125909593.SGD","LU1929549753.HKD","LU0965509283.SGD","MRK","SG9999001176.SGD","LU2361045086.USD","LU1037948541.HKD","IE00B1BXHZ80.USD","LU2357627491.SGD","IE00BSNM7G36.USD","LU0130517989.USD","LU0965509010.AUD","LU0289739699.SGD","SG9999001440.SGD","LU1934455863.HKD","LU2112291526.USD","BK4559","LU1430594728.SGD","LU2125909247.SGD","LU2324357040.USD","LU0122379950.USD","LU0868494708.USD","LU0432979614.USD","LU2433249047.HKD","BK4534","LU1934455194.USD","LU1571399168.USD","LU0203345920.USD","LU2491050071.SGD","LU0265550359.USD","LU2361044865.SGD","LU2148510915.USD","LU1066051498.USD","IE00BBT3K403.USD","BK0239","LU0106261372.USD","LU0861579265.USD","LU1037948897.HKD","LU2125154778.USD","LU1057294990.SGD","LU0320765489.SGD","LU0006306889.USD","LU1934455277.USD","LU1923622614.USD","SG9999014542.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","LU1585245621.USD","LU0965509101.SGD","IE00BLSP4239.USD","SG9999013999.USD","LU1061106388.HKD","LU0965508806.USD","SGXZ57979304.SGD","SG9999002232.USD","BK4585","002422","LU2491050154.USD","LU1116320737.USD","SG9999015341.SGD","LU0266013472.USD","LU1116320901.HKD","LU1064130708.USD","IE00BN8TJ469.HKD","LU0234572021.USD","LU2468319806.SGD","LU2491049909.HKD","SG9999014567.USD","BK4588","LU1093756168.USD","IE00B4R5TH58.HKD","LU0238689110.USD","SG9999014575.USD","LU0203347892.USD","LU0211331839.USD","LU0265550946.USD","LU1066051811.HKD","SG9999001176.USD","IE00BFTCPJ56.SGD","LU0942090050.USD","LU0980610538.SGD","LU1989772923.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU0859254822.USD","LU1162221912.USD","LU1934453819.USD","LU1093756325.SGD","LU1979443071.USD","LU1201861249.SGD","LU1941712348.USD","LU0320765646.SGD","LU2023250843.SGD","LU0058720904.USD","LU1941712264.USD","BK0060","LU0208291251.USD","LU2361044949.HKD","LU1917777945.USD","LU0070302665.USD","IE0002141913.USD","LU0098860793.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186797770","title":"异动解读 | 肺癌联合疗法III期试验成功，默沙东盘中大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186797770","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186797770?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:13","pubTimestamp":1779459210,"startTime":"0","endTime":"0","summary":"默沙东今日盘中股价大涨5.01%，引起了市场的高度关注。该联合疗法达到了试验的主要终点，与单用Keytruda相比，显著降低了患者疾病进展或死亡的风险约65%，这被分析师评价为“极具鼓舞性”的数据，并被视为肺癌治疗领域的一项重要进展。此外，默沙东近期在其他肿瘤管线也传出利好，包括Keytruda联合Padcev用于膀胱癌的疗法获得欧盟监管机构的积极意见，以及其TROP2靶向ADC在子宫内膜癌的III期试验中达到双重主要终点。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152994441","title":"默沙东癌症疗法获积极进展 市场关注度升温","url":"https://stock-news.laohu8.com/highlight/detail?id=1152994441","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152994441?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:59","pubTimestamp":1779458348,"startTime":"0","endTime":"0","summary":"美国临床肿瘤学会发布的一项研究摘要，被摩根大通分析师评价为“极具鼓舞性”。这项名为sac-TMT的靶向化疗方案由默沙东与中国生物科技公司科伦博泰联合开发。分析师指出：“在联合患者群体中，sac-TMT将死亡或疾病进展风险降低了65%。”不过他们也补充说明，该药物的对照对象是默沙东自身的Keytruda单药疗法，而此方案并非全球多数地区的标准治疗方案，这使直接比较变得复杂。尽管如此，分析师强调：“数据本身依然坚实……并持续降低了sac-TMT的研发风险。”受此消息提振，默沙东股价上涨4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1524d98f25a887386dd8f38c500227b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0965509010.AUD","LU2106854487.HKD","LU0432979614.USD","LU2089984988.USD","LU1291159041.SGD","SG9999002232.USD","IE00BLSP4452.SGD","LU2361044865.SGD","LU0320765646.SGD","LU0266013472.USD","LU0106261372.USD","SG9999002224.SGD","LU2360032135.SGD","LU2125909593.SGD","SG9999015341.SGD","LU0868494708.USD","LU0942090050.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU1929549753.HKD","LU1066051811.HKD","LU1037948897.HKD","LU0861579265.USD","LU1430594728.SGD","LU1069347547.HKD","SG9999014559.SGD","LU1116320737.USD","LU1983299246.USD","LU0203345920.USD","LU2112291526.USD","LU0058720904.USD","LU0265550946.USD","IE00BSNM7G36.USD","SG9999014575.USD","LU1974910355.USD","LU1989772840.SGD","LU2491050154.USD","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU2361045086.USD","LU2433249047.HKD","SG9999014567.USD","LU0868494617.USD","IE00BBT3K403.USD","LU2491050071.SGD","LU0130102774.USD","LU1934455277.USD","LU2125154935.USD","LU1934455194.USD","LU2125909247.SGD","SG9999001440.SGD","SG9999013999.USD","LU1093756325.SGD","LU1941712264.USD","LU1037948541.HKD","SG9999001176.SGD","LU0859254822.USD","BK4588","LU0980610538.SGD","LU1989772923.USD","IE00B2B36J28.USD","LU1923622614.USD","MRK","LU1917777945.USD","LU2357627491.SGD","LU0965508806.USD","LU0965509101.SGD","LU1934455863.HKD","LU1941712348.USD","LU2023250504.SGD","LU1023059063.AUD","LU0211331839.USD","LU1989771016.USD","SGXZ57979304.SGD","LU2361044949.HKD","LU1201861249.SGD","LU0320765489.SGD","LU0234572021.USD","LU1116320901.HKD","SG9999014542.SGD","LU2125154778.USD","LU0208291251.USD","BK4516","IE0002141913.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU1066053197.SGD","LU2461242641.AUD","LU1093756168.USD","LU2324357040.USD","LU0985320562.USD","IE0009355771.USD","LU0098860793.USD","LU1061106388.HKD","LU1585245621.USD","BK4550","IE00BN8TJ469.HKD","LU1162221912.USD","BK4533","LU2491049909.HKD","BK4534","LU1035773651.USD","LU0122379950.USD","LU0203347892.USD","LU0130517989.USD","LU0648001328.SGD","BK4585","LU0006306889.USD","LU0070302665.USD","LU1066051225.USD","IE00B1BXHZ80.USD","SG9999015358.SGD","LU1571399168.USD","LU0289739699.SGD","LU1699723380.USD","LU1057294990.SGD","LU1066051498.USD","LU0965509283.SGD","LU0265550359.USD","LU2468319806.SGD","BK4559","LU2023250843.SGD","LU0477156953.USD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108440543","title":"异动解读｜默沙东盘中上涨4.5%，TROP2 ADC子宫内膜癌III期试验达双重主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1108440543","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108440543?lang=zh_cn&edition=full","pubTime":"2026-05-22 21:33","pubTimestamp":1779456791,"startTime":"0","endTime":"0","summary":"5月22日，默沙东盘中上涨4.5%，报120.93美元/股，成交额1798.22万美元。消息面上，默沙东宣布其与科伦博泰合作开发的TROP2靶向抗体偶联药物Sacituzumab Tirumotecan，在针对晚期或复发性子宫内膜癌患者的全球III期TroFuse-005试验中，达到了总生存期与无进展生存期双重主要终点，同时达到客观缓解率次要终点。TroFuse-005是首个在该类患者中相较化疗同时实现OS和PFS统计学显著改善的全球III期试验，进一步验证了默沙东在ADC管线上的布局潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631481","title":"默沙东肺癌联合疗法III期研究成功，肿瘤进展风险降低65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631481","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637631481?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:34","pubTimestamp":1779453240,"startTime":"0","endTime":"0","summary":"默沙东于5月21日宣布，其与科伦博泰合作开发的抗体偶联药物sacituzumab tirumotecan联合Keytruda，在治疗非小细胞肺癌的III期研究中取得积极结果。受此消息提振，默沙东股价当日上涨逾3%。 研究数据显示，与Keytruda单药治疗相比，sac-TMT联合疗法可将患者的疾病进展或死亡风险显著降低65%。联合治疗组的客观缓解率达70.2%，而Keytruda单药组为42%。目前该联合疗法已在中国提交上市申请并获优先审评资格，详细数据将在2026年ASCO年会上公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyurwe8323384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1066051498.USD","LU1291159041.SGD","LU1069347547.HKD","LU1093756168.USD","IE00BN8TJ469.HKD","LU1066051225.USD","SG9999014559.SGD","LU0868494708.USD","LU0130102774.USD","LU1699723380.USD","LU1974910355.USD","LU1934455863.HKD","LU0130517989.USD","LU1201861249.SGD","IE00BSNM7G36.USD","LU0965509101.SGD","BK4533","LU1023059063.AUD","LU1162221912.USD","LU0122379950.USD","LU0320765489.SGD","SG9999002232.USD","LU2125154778.USD","LU1057294990.SGD","BK4534","BK4585","LU0868494617.USD","IE00BJJMRZ35.SGD","LU2468319806.SGD","SGXZ57979304.SGD","LU1983299246.USD","LU2491050154.USD","LU2360032135.SGD","IE00BBT3K403.USD","LU0859254822.USD","LU1066051811.HKD","SG9999013999.USD","BK4559","IE00BFTCPJ56.SGD","SG9999015358.SGD","LU1066053197.SGD","IE000M9KFDE8.USD","BK4550","LU0208291251.USD","LU2461242641.AUD","LU2112291526.USD","LU0477156953.USD","LU0965509010.AUD","LU1571399168.USD","LU2361044949.HKD","LU2491050071.SGD","LU1929549753.HKD","LU2324357040.USD","LU1934455194.USD","LU0265550946.USD","LU0965509283.SGD","LU1989772923.USD","LU0106261372.USD","LU0965508806.USD","LU2357627491.SGD","SG9999001176.USD","IE00BLSP4452.SGD","SG9999001176.SGD","LU1093756325.SGD","LU0203345920.USD","LU1585245621.USD","LU0098860793.USD","BK4588","LU1923622614.USD","LU0980610538.SGD","LU2361044865.SGD","IE0009355771.USD","LU2491049909.HKD","LU0238689110.USD","BK4516","IE00BLSP4239.USD","LU0070302665.USD","LU1917777945.USD","SG9999015341.SGD","LU2023250504.SGD","LU0266013472.USD","LU1989771016.USD","LU0432979614.USD","LU1941712348.USD","LU0648001328.SGD","SG9999014542.SGD","LU2106854487.HKD","SG9999014567.USD","LU0320765646.SGD","IE0002141913.USD","LU1037948541.HKD","MRK","SG9999014575.USD","BK4007","LU2433249047.HKD","IE00B2B36J28.USD","LU2125909593.SGD","LU1934455277.USD","LU2125909247.SGD","LU0203347892.USD","LU1035773651.USD","SG9999002224.SGD","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0234572021.USD","LU1116320737.USD","LU0058720904.USD","LU2023250843.SGD","LU2089984988.USD","LU0985320562.USD","LU1061106388.HKD","LU1941712264.USD","LU2125154935.USD","IE00BJT1NW94.SGD","LU0265550359.USD","LU2361045086.USD","IE00B1BXHZ80.USD","LU0006306889.USD","LU0211331839.USD","LU0861579265.USD","LU0942090050.USD","SG9999001440.SGD","LU1430594728.SGD","LU1116320901.HKD","LU1037948897.HKD","LU1989772840.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169778338","title":"默沙东Keytruda®联合Padcev®获欧盟CHMP积极意见，用于顺铂不适切可切除肌层浸润性膀胱癌成人围手术期治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1169778338","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169778338?lang=zh_cn&edition=full","pubTime":"2026-05-22 19:56","pubTimestamp":1779451013,"startTime":"0","endTime":"0","summary":"默沙东宣布，其药物Keytruda®（帕博利珠单抗）联合Padcev®（enfortumab vedotin-ejfv）用于治疗顺铂不适切的可切除肌层浸润性膀胱癌成人患者的围手术期治疗方案，已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见。这一进展为治疗方案在欧洲的最终获批铺平了道路，有望为特定膀胱癌患者群体提供一种重要的新治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU2324357040.USD","SG9999001176.USD","LU0070302665.USD","LU0122379950.USD","LU0208291251.USD","LU1941712348.USD","LU0234572021.USD","SG9999002224.SGD","LU2491050154.USD","LU2125909247.SGD","LU0265550946.USD","LU2491050071.SGD","LU2023250504.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","BK4534","LU1037948897.HKD","LU0320765646.SGD","SG9999015358.SGD","LU0320765489.SGD","LU0985320562.USD","LU1023059063.AUD","LU0942090050.USD","LU0965509283.SGD","LU0432979614.USD","LU2361045086.USD","LU1066051498.USD","IE00B4R5TH58.HKD","LU1430594728.SGD","LU1923622614.USD","LU1066051225.USD","LU2023250843.SGD","LU0130517989.USD","LU0965509101.SGD","LU1989772923.USD","LU1941712264.USD","LU0098860793.USD","LU0477156953.USD","BK4585","SG9999015341.SGD","LU0106261372.USD","IE00BJJMRZ35.SGD","BK4007","LU1066053197.SGD","LU1116320737.USD","LU2357627491.SGD","LU1037948541.HKD","LU1917777945.USD","LU2125909593.SGD","IE0002141913.USD","LU0980610538.SGD","SGXZ57979304.SGD","SG9999014559.SGD","LU1057294990.SGD","SG9999001176.SGD","BK4559","LU0965508806.USD","LU1093756168.USD","LU1989772840.SGD","LU2468319806.SGD","LU0238689110.USD","LU0006306889.USD","LU2491049909.HKD","BK4550","LU1116320901.HKD","SG9999013999.USD","MRK","LU1201861249.SGD","IE00B2B36J28.USD","LU2106854487.HKD","LU2125154778.USD","LU1069347547.HKD","LU0965509010.AUD","IE00BBT3K403.USD","LU2089984988.USD","LU0861579265.USD","LU0868494617.USD","LU0648001328.SGD","SG9999001440.SGD","LU1934455863.HKD","SG9999014542.SGD","IE00BSNM7G36.USD","LU1066051811.HKD","LU1291159041.SGD","LU1571399168.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","SG9999014575.USD","LU2125154935.USD","BK4516","LU1162221912.USD","IE00BFTCPJ56.SGD","IE00BN8TJ469.HKD","LU0266013472.USD","SG9999014567.USD","LU2361044949.HKD","BK4533","LU0868494708.USD","IE000M9KFDE8.USD","LU2360032135.SGD","BK4588","LU0265550359.USD","LU0203347892.USD","LU1035773651.USD","SG9999002232.USD","LU0211331839.USD","LU1983299246.USD","IE00B1BXHZ80.USD","LU1585245621.USD","LU1699723380.USD","LU1929549753.HKD","LU1989771016.USD","LU0130102774.USD","IE0009355771.USD","LU2433249047.HKD","LU2361044865.SGD","LU0058720904.USD","LU1974910355.USD","LU1093756325.SGD","LU0203345920.USD","LU0859254822.USD","LU1061106388.HKD","LU1934455277.USD","LU1934455194.USD","LU2461242641.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113236694","title":"合作方科伦药业肺癌联合疗法达成晚期试验目标，默沙东股价盘前大涨3.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113236694","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113236694?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:10","pubTimestamp":1779444646,"startTime":"0","endTime":"0","summary":"默沙东与其合作伙伴科伦药业共同研发的肺癌联合疗法，已成功达成一项关键晚期临床试验的主要目标。受此积极消息推动，默沙东股价在盘前交易时段应声上涨3.7%。该疗法在晚期试验中展现出的潜力，为后续的监管审批与商业化进程奠定了坚实基础，也提振了市场对该公司肿瘤管线前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","BK4007","IE00BN8TJ469.HKD","LU1934455863.HKD","LU1035773651.USD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU2361044949.HKD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2491049909.HKD","SG9999015358.SGD","LU2361044865.SGD","SG9999014575.USD","LU2491050154.USD","BK4585","LU0965509283.SGD","LU1989772923.USD","LU0058720904.USD","LU0320765646.SGD","LU1989771016.USD","LU2468319806.SGD","LU2433249047.HKD","LU0266013472.USD","LU0965508806.USD","LU0203347892.USD","SG9999001440.SGD","LU1989772840.SGD","IE0002141913.USD","LU1093756325.SGD","SG9999013999.USD","IE00BSNM7G36.USD","LU1093756168.USD","LU2023250843.SGD","LU2324357040.USD","LU0006306889.USD","IE000M9KFDE8.USD","LU0965509010.AUD","BK4516","LU0130102774.USD","SG9999015341.SGD","SG9999002224.SGD","SG9999001176.SGD","LU0070302665.USD","LU1162221912.USD","LU1291159041.SGD","LU0238689110.USD","LU1057294990.SGD","LU1571399168.USD","LU1929549753.HKD","LU0098860793.USD","LU1941712348.USD","SG9999014567.USD","LU1941712264.USD","LU1201861249.SGD","BK4533","SG9999001176.USD","LU0648001328.SGD","MRK","LU0265550359.USD","LU0942090050.USD","LU1037948897.HKD","LU0203345920.USD","LU0234572021.USD","LU0868494708.USD","BK4559","IE00BJT1NW94.SGD","LU1116320737.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU2023250504.SGD","LU1430594728.SGD","LU1983299246.USD","LU2125909247.SGD","LU1023059063.AUD","LU2089984988.USD","LU1934455277.USD","LU0211331839.USD","LU1066053197.SGD","LU0477156953.USD","SG9999014559.SGD","LU0320765489.SGD","IE00B1BXHZ80.USD","LU0122379950.USD","LU1699723380.USD","LU1974910355.USD","LU2357627491.SGD","LU1585245621.USD","LU1069347547.HKD","SG9999002232.USD","LU0859254822.USD","LU1037948541.HKD","LU0861579265.USD","BK4588","LU1917777945.USD","LU2491050071.SGD","LU2125154778.USD","LU2106854487.HKD","LU2361045086.USD","LU0289739699.SGD","LU1934455194.USD","LU1066051498.USD","LU0868494617.USD","LU1066051811.HKD","SG9999014542.SGD","LU1066051225.USD","LU0985320562.USD","IE00BLSP4452.SGD","LU0106261372.USD","LU1923622614.USD","LU0208291251.USD","LU0980610538.SGD","IE00BLSP4239.USD","LU0265550946.USD","LU0965509101.SGD","LU1116320901.HKD","LU1061106388.HKD","LU2461242641.AUD","BK4534","LU2125909593.SGD","LU2112291526.USD","LU2125154935.USD","LU2360032135.SGD","BK4550","LU0432979614.USD","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174026782","title":"异动解读｜默沙东盘前上涨3.18%，TROP2 ADC子宫内膜癌III期试验达双重主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1174026782","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174026782?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:46","pubTimestamp":1779443195,"startTime":"0","endTime":"0","summary":"5月22日，默沙东盘前上涨3.18%，报119.61美元/股，成交额50.76万美元。消息面上，默沙东宣布其与科伦博泰合作开发的TROP2靶向抗体偶联药物Sacituzumab Tirumotecan，在针对晚期或复发性子宫内膜癌患者的全球III期TroFuse-005试验中，达到了总生存期与无进展生存期双重主要终点，同时达到客观缓解率次要终点。与医生选择疗法相比，Sac-TMT在两项主要指标上均显示出统计学显著且具有临床意义的改善，安全性与既往研究一致。该数据进一步验证了默沙东在ADC管线上的布局潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146335978","title":"异动解读｜默沙东盘后上涨3.11%，TROP2 ADC子宫内膜癌III期试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1146335978","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146335978?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:18","pubTimestamp":1779398316,"startTime":"0","endTime":"0","summary":"5月22日，默沙东盘后上涨3.11%，报119.53美元/股，成交额5342.41万美元。消息面上，默沙东宣布其与科伦博泰合作开发的TROP2靶向抗体偶联药物Sacituzumab Tirumotecan在针对晚期或复发性子宫内膜癌的全球III期TroFuse-005试验中，达到了总生存期与无进展生存期双重主要终点，同时达到客观缓解率次要终点。与医生选择疗法相比，Sac-TMT在两项主要指标上均显示出统计学显著且具有临床意义的改善，安全性与既往研究一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105243252","title":"科伦博泰生物与默沙东联合疗法安全性概览：Sac-TMT联合帕博利珠单抗总体可控，与各组分已知安全性特征一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1105243252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105243252?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:04","pubTimestamp":1779397489,"startTime":"0","endTime":"0","summary":"科伦博泰生物与默沙东联合开发的Sac-TMT与帕博利珠单抗（Pembrolizumab）联合治疗方案，其安全性特征总体而言是可控的。观察到的安全性数据与各单药组分已知的安全性特征保持一致，未出现超出预期的新的安全性信号。这一结果表明，该联合疗法的安全性在临床上处于可管理范畴，为其进一步的临床开发与应用提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2433249047.HKD","LU1066051225.USD","IE00B2B36J28.USD","LU0211331839.USD","BK4007","LU0980610538.SGD","LU1066051811.HKD","LU1093756168.USD","LU1066051498.USD","BK4585","MRK","IE00B4R5TH58.HKD","LU1699723380.USD","06990","SG9999014575.USD","LU0006306889.USD","LU2125909593.SGD","LU2461242641.AUD","LU1989771016.USD","LU1069347547.HKD","LU1037948541.HKD","LU1941712348.USD","SG9999002232.USD","LU0432979614.USD","SG9999013999.USD","LU0196878994.USD","LU1162221912.USD","SGXZ57979304.SGD","LU0965509010.AUD","LU0130102774.USD","LU0203345920.USD","LU1093756325.SGD","LU0098860793.USD","LU2324357040.USD","LU1291159041.SGD","LU0208291251.USD","LU1116320737.USD","LU2089984988.USD","LU0265550359.USD","LU0058720904.USD","LU1037948897.HKD","LU1066053197.SGD","LU1934455277.USD","SG9999001440.SGD","LU0106261372.USD","LU2360032135.SGD","LU2361044865.SGD","LU0122379950.USD","LU2357627491.SGD","LU1571399168.USD","IE0002141913.USD","LU0265550946.USD","LU0320765646.SGD","LU2491050071.SGD","LU0942090050.USD","LU0238689110.USD","LU1989772923.USD","IE00BFTCPJ56.SGD","LU2491049909.HKD","LU0965508806.USD","SG9999014567.USD","SG9999001176.SGD","LU0070302665.USD","SG9999015358.SGD","BK4588","SG9999002224.SGD","LU2125909247.SGD","LU1201861249.SGD","IE00BSNM7G36.USD","LU2106854487.HKD","IE000M9KFDE8.USD","SG9999001176.USD","LU1023059063.AUD","LU2361045086.USD","BK4550","LU1989772840.SGD","LU0130517989.USD","LU0320765489.SGD","LU0289739699.SGD","LU0203347892.USD","LU1035773651.USD","LU2361044949.HKD","LU0965509283.SGD","LU0965509101.SGD","LU1061106388.HKD","LU1057294990.SGD","LU1934455863.HKD","LU0861579265.USD","IE00B1BXHZ80.USD","LU0859254822.USD","IE00BLSP4239.USD","BK4533","LU0985320562.USD","LU2125154935.USD","LU1430594728.SGD","LU0477156953.USD","LU1983299246.USD","LU2125154778.USD","IE00BJJMRZ35.SGD","SG9999014559.SGD","IE00BJT1NW94.SGD","BK4534","BK4559","LU0868494708.USD","LU1917777945.USD","LU2023250504.SGD","LU0266013472.USD","LU1934455194.USD","LU0868494617.USD","LU1941712264.USD","IE00BN8TJ469.HKD","BK4516","LU2112291526.USD","SG9999014542.SGD","LU1585245621.USD","LU0648001328.SGD","LU1116320901.HKD","SG9999015341.SGD","LU2023250843.SGD","IE00BBT3K403.USD","IE0009355771.USD","LU1923622614.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU2491050154.USD","LU1974910355.USD","LU2468319806.SGD","BK1161","LU1929549753.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637780378","title":"港股异动 | 科伦博泰生物(06990)涨超5% 与默沙东合作的TROP2 ADC全球III期研究达成主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2637780378","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637780378?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:58","pubTimestamp":1779332292,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超5%，截至发稿，涨3.3%，报451.4港元，成交额1.66亿港元。消息面上，近日，据科伦博泰生物官微消息，默沙东宣布，与公司合作开发的在研TROP2靶向抗体药物偶联物sacituzumab tirumotecan，在针对某些晚期或复发性子宫内膜癌患者的关键性III期TroFuse-005试验中，达到了总生存期和无进展生存期的主要终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","SG9999014542.SGD","LU2023250504.SGD","LU2491050071.SGD","SG9999014559.SGD","LU0265550946.USD","IE00BFTCPJ56.SGD","SG9999015358.SGD","LU2360032135.SGD","LU2125909247.SGD","SG9999002224.SGD","LU0130517989.USD","LU0965509283.SGD","LU1989772840.SGD","LU2491050154.USD","LU0234572021.USD","LU1571399168.USD","LU0130102774.USD","LU1116320737.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU1066051811.HKD","IE000M9KFDE8.USD","LU2125154935.USD","BK4588","SG9999015341.SGD","LU0868494708.USD","LU1941712264.USD","BK4007","LU1093756325.SGD","BK4134","IE00BBT3K403.USD","LU1291159041.SGD","SG9999014567.USD","LU2089984988.USD","LU0196878994.USD","LU2433249047.HKD","SG9999014575.USD","LU1037948897.HKD","LU2361044865.SGD","LU2361045086.USD","LU0106261372.USD","LU1057294990.SGD","MRK","LU2106854487.HKD","LU2125909593.SGD","LU1699723380.USD","SG9999013999.USD","LU0265550359.USD","LU0208291251.USD","LU2461242641.AUD","IE0002141913.USD","LU0098860793.USD","LU0211331839.USD","LU0238689110.USD","LU1023059063.AUD","LU1983299246.USD","06990","LU0058720904.USD","IE00BLSP4239.USD","LU0203347892.USD","LU1162221912.USD","BK4550","LU1989771016.USD","LU2491049909.HKD","LU1934455863.HKD","BK4080","LU1430594728.SGD","LU1989772923.USD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU0320765646.SGD","BK1161","LU1035773651.USD","LU1974910355.USD","LU2125154778.USD","LU1066053197.SGD","LU1116320901.HKD","LU2023250843.SGD","LU1066051498.USD","BK4516","BK4533","BK4585","LU0861579265.USD","LU0965508806.USD","LU1941712348.USD","LU0859254822.USD","LU1929549753.HKD","LU1585245621.USD","LU0477156953.USD","LU0965509010.AUD","IE00B2B36J28.USD","LU0320765489.SGD","LU1093756168.USD","BK4534","LU1201861249.SGD","BK4559","LU1069347547.HKD","LU0980610538.SGD","LU1934455277.USD","LU2324357040.USD","SG9999002232.USD","LU0070302665.USD","LU0985320562.USD","LU0868494617.USD","IE0009355771.USD","LU1066051225.USD","LU1934455194.USD","LU0203345920.USD","LU0122379950.USD","LU2361044949.HKD","LU0266013472.USD","BK4231","IE00BLSP4452.SGD","LU0648001328.SGD","LU1061106388.HKD","LU1923622614.USD","SG9999001440.SGD","LU0289739699.SGD","IE00BN8TJ469.HKD","LU0006306889.USD","LU0965509101.SGD","LU2468319806.SGD","SG9999001176.USD","SG9999001176.SGD","LU1917777945.USD","LU2112291526.USD","LU0942090050.USD","LU2357627491.SGD","SGXZ57979304.SGD","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182393564","title":"国家广告审查委员会就Bravecto Quantum剂量宣称问题 将默沙东动物保健部门提交FTC及FDA处理","url":"https://stock-news.laohu8.com/highlight/detail?id=1182393564","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182393564?lang=zh_cn&edition=full","pubTime":"2026-05-20 23:03","pubTimestamp":1779289387,"startTime":"0","endTime":"0","summary":"国家广告审查委员会已决定，将默沙东（Merck）旗下动物保健部门关于其产品Bravecto Quantum的剂量相关宣传主张，提交给美国联邦贸易委员会（FTC）及美国食品药品监督管理局（FDA）进行进一步审查与处理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455863.HKD","SG9999001440.SGD","LU1917777945.USD","LU1934455194.USD","LU0265550359.USD","LU2468319806.SGD","SG9999013999.USD","LU1571399168.USD","LU1941712264.USD","LU0980610538.SGD","IE00BLSP4239.USD","LU0320765489.SGD","LU1023059063.AUD","LU2023250504.SGD","LU0203347892.USD","LU0238689110.USD","LU2125154935.USD","MRK","SG9999014567.USD","LU2361044865.SGD","LU2357627491.SGD","LU1035773651.USD","LU0432979614.USD","LU2361044949.HKD","LU1974910355.USD","IE00BSNM7G36.USD","LU1989772923.USD","LU2089984988.USD","BK4007","LU2106854487.HKD","LU1983299246.USD","BK4516","LU1923622614.USD","LU2125909593.SGD","LU2491049909.HKD","SG9999002232.USD","LU0868494617.USD","BK4550","LU2125154778.USD","LU1116320901.HKD","LU0006306889.USD","LU1066051225.USD","LU1162221912.USD","LU2125909247.SGD","LU1069347547.HKD","LU2112291526.USD","BK4533","SG9999014575.USD","LU2433249047.HKD","SG9999001176.USD","LU0266013472.USD","LU0130102774.USD","LU1061106388.HKD","LU0985320562.USD","LU1037948541.HKD","LU0965509283.SGD","LU0942090050.USD","LU1989771016.USD","LU0122379950.USD","LU0648001328.SGD","LU0203345920.USD","IE00BLSP4452.SGD","SG9999014542.SGD","LU1699723380.USD","LU0211331839.USD","LU2023250843.SGD","LU1057294990.SGD","BK4559","LU1201861249.SGD","LU0070302665.USD","LU0265550946.USD","LU2361045086.USD","SG9999002224.SGD","LU0289739699.SGD","IE0002141913.USD","SG9999015358.SGD","LU1989772840.SGD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU1929549753.HKD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1037948897.HKD","IE00B4R5TH58.HKD","LU2491050071.SGD","LU0130517989.USD","IE0009355771.USD","LU1066051811.HKD","IE00B1BXHZ80.USD","LU1093756168.USD","LU0208291251.USD","LU0965509101.SGD","LU2360032135.SGD","SG9999014559.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0477156953.USD","LU0234572021.USD","SG9999001176.SGD","LU0106261372.USD","LU2491050154.USD","LU0320765646.SGD","LU0965509010.AUD","LU1116320737.USD","IE00BBT3K403.USD","LU0965508806.USD","LU1430594728.SGD","LU0098860793.USD","LU1941712348.USD","LU1093756325.SGD","SG9999015341.SGD","IE00BN8TJ469.HKD","LU0868494708.USD","LU0859254822.USD","BK4588","LU0058720904.USD","LU1066053197.SGD","LU0861579265.USD","BK4534","LU2461242641.AUD","LU1066051498.USD","BK4585","LU1934455277.USD","IE00BJJMRZ35.SGD","LU2324357040.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140623873","title":"世卫组织驻刚果代表：默沙东Ervebo是潜在可预防埃博拉病毒的疫苗之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1140623873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140623873?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:58","pubTimestamp":1779184699,"startTime":"0","endTime":"0","summary":"世界卫生组织驻刚果（金）代表指出，默沙东公司研发的Ervebo疫苗，属于有望为埃博拉病毒提供预防与保护的潜在候选疫苗之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2491049909.HKD","LU1066051811.HKD","LU0320765646.SGD","BK4516","LU1061106388.HKD","IE00BLSP4239.USD","LU2125909593.SGD","LU1983299246.USD","LU0203347892.USD","BK4559","LU0648001328.SGD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU2125909247.SGD","LU2361045086.USD","IE00BJT1NW94.SGD","LU2361044949.HKD","LU1989772923.USD","LU2357627491.SGD","SG9999001176.USD","LU0861579265.USD","LU0320765489.SGD","LU1929549753.HKD","LU1035773651.USD","LU2461242641.AUD","SG9999015358.SGD","SG9999014559.SGD","LU1066051498.USD","LU1069347547.HKD","LU1941712264.USD","IE0009355771.USD","LU0289739699.SGD","LU1093756168.USD","LU0965509010.AUD","LU1989771016.USD","MRK","SG9999014575.USD","LU0965509283.SGD","LU1162221912.USD","LU2125154935.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0265550359.USD","BK4533","LU0006306889.USD","LU1066051225.USD","LU2125154778.USD","IE0002141913.USD","LU0980610538.SGD","LU2324357040.USD","LU2023250504.SGD","LU1116320901.HKD","LU1989772840.SGD","LU1934455194.USD","IE000M9KFDE8.USD","LU0211331839.USD","LU2112291526.USD","LU2491050071.SGD","LU1934455863.HKD","SGXZ57979304.SGD","LU0238689110.USD","LU0868494708.USD","SG9999014542.SGD","LU2361044865.SGD","IE00B4R5TH58.HKD","LU1093756325.SGD","LU1923622614.USD","IE00BLSP4452.SGD","LU1201861249.SGD","IE00BSNM7G36.USD","LU1571399168.USD","LU1917777945.USD","LU0965508806.USD","LU0098860793.USD","LU0130517989.USD","LU0266013472.USD","SG9999015341.SGD","LU2106854487.HKD","LU0477156953.USD","LU0265550946.USD","LU0942090050.USD","IE00B1BXHZ80.USD","LU0859254822.USD","LU0106261372.USD","IE00BBT3K403.USD","LU1934455277.USD","LU1974910355.USD","LU1699723380.USD","LU1585245621.USD","LU1023059063.AUD","BK4550","IE00B2B36J28.USD","LU2468319806.SGD","LU0203345920.USD","LU1037948897.HKD","LU1037948541.HKD","SG9999013999.USD","BK4588","LU0868494617.USD","LU2023250843.SGD","BK4007","SG9999014567.USD","LU1941712348.USD","LU1291159041.SGD","SG9999002232.USD","LU1066053197.SGD","LU2089984988.USD","IE00BN8TJ469.HKD","LU1116320737.USD","LU2433249047.HKD","SG9999002224.SGD","BK4534","LU0965509101.SGD","SG9999001176.SGD","LU0208291251.USD","LU1430594728.SGD","LU0432979614.USD","LU0122379950.USD","LU2491050154.USD","BK4585","LU0985320562.USD","LU2360032135.SGD","LU0130102774.USD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636006648","title":"默沙东ADC癌症新药再下一城，子宫内膜癌III期研究大获成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006648","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636006648?lang=zh_cn&edition=full","pubTime":"2026-05-19 03:46","pubTimestamp":1779133560,"startTime":"0","endTime":"0","summary":" 默沙东与科伦博泰近日宣布，其合作开发的TROP2靶向抗体偶联药物Sac-TMT在III期TroFuse-005试验中取得积极结果。该研究针对的是已经接受过铂类化疗和免疫治疗后病情进展的晚期或复发性子宫内膜癌患者，这也是当前治疗选择非常有限的难治人群。 TroFuse-005是默沙东围绕Sac-TMT搭建的大型临床开发项目——TroFuse计划中的首个成功读出III期数据的研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-19/doc-inhykhiz7760343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BN8TJ469.HKD","LU0942090050.USD","BK4559","LU2125909247.SGD","IE00BFTCPJ56.SGD","LU0432979614.USD","LU0965509010.AUD","BK4080","LU0265550359.USD","SG9999015358.SGD","LU0130517989.USD","LU1066051498.USD","IE00BJJMRZ35.SGD","LU1941712264.USD","LU2361044949.HKD","LU0203345920.USD","LU1941712348.USD","LU0320765489.SGD","LU1917777945.USD","SG9999002232.USD","LU0965509101.SGD","LU1989771016.USD","SGXZ57979304.SGD","IE00B1BXHZ80.USD","IE0009355771.USD","LU1023059063.AUD","LU0098860793.USD","LU0106261372.USD","LU2106854487.HKD","LU1093756168.USD","LU2112291526.USD","LU1989772923.USD","BK4585","LU2023250504.SGD","LU2324357040.USD","LU0985320562.USD","LU0265550946.USD","LU2361044865.SGD","LU0868494617.USD","LU1069347547.HKD","IE00B4R5TH58.HKD","LU2360032135.SGD","LU1923622614.USD","LU2461242641.AUD","LU2491050071.SGD","LU1035773651.USD","LU1066051811.HKD","LU0868494708.USD","IE00B2B36J28.USD","LU1934455863.HKD","SG9999014567.USD","LU1162221912.USD","MRK","LU1116320737.USD","LU0122379950.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","BK4588","IE00BLSP4452.SGD","LU1061106388.HKD","LU1066053197.SGD","LU1929549753.HKD","LU0070302665.USD","LU1989772840.SGD","SG9999015341.SGD","LU1057294990.SGD","LU0859254822.USD","LU2023250843.SGD","LU0965508806.USD","LU1066051225.USD","SG9999014559.SGD","LU0203347892.USD","LU2089984988.USD","LU0234572021.USD","SG9999001440.SGD","SG9999014575.USD","BK4516","LU0477156953.USD","IE00BBT3K403.USD","LU2468319806.SGD","LU2491049909.HKD","LU0208291251.USD","BK4533","LU1934455277.USD","LU2433249047.HKD","LU0006306889.USD","LU0130102774.USD","BK4534","LU1699723380.USD","LU2125154778.USD","LU2491050154.USD","LU0980610538.SGD","LU1974910355.USD","SG9999002224.SGD","BK4550","LU0238689110.USD","LU1430594728.SGD","LU1571399168.USD","LU0320765646.SGD","LU0648001328.SGD","LU2125154935.USD","SG9999013999.USD","IE00BLSP4239.USD","SG9999001176.SGD","IE00BSNM7G36.USD","LU0861579265.USD","LU1037948897.HKD","LU1116320901.HKD","LU2357627491.SGD","LU1934455194.USD","LU2125909593.SGD","LU1585245621.USD","LU1983299246.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU1037948541.HKD","BK4007","LU1201861249.SGD","IE0002141913.USD","LU1291159041.SGD","SG9999014542.SGD","BK4231","LU1093756325.SGD","SG9999001176.USD","LU0211331839.USD","LU2361045086.USD","BK4134","LU0965509283.SGD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.merck.com","stockEarnings":[{"period":"1week","weight":-0.034},{"period":"1month","weight":0.0311},{"period":"3month","weight":-0.0385},{"period":"6month","weight":0.1463},{"period":"1year","weight":0.5167},{"period":"ytd","weight":0.0987}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"默克制药公司于1970年在新泽西州注册成立。该公司是一家全球医疗保健公司，通过其处方药提供创新的健康解决方案，包括生物疗法、疫苗和动物保健产品。该公司的营运主要以产品为基础进行管理，包括两个经营分部：制药及动物保健国际。","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.010352},{"month":2,"riseRate":0.456522,"avgChangeRate":0.000847},{"month":3,"riseRate":0.608696,"avgChangeRate":-0.003426},{"month":4,"riseRate":0.595745,"avgChangeRate":0.014758},{"month":5,"riseRate":0.638298,"avgChangeRate":0.017693},{"month":6,"riseRate":0.510638,"avgChangeRate":0.012203},{"month":7,"riseRate":0.478261,"avgChangeRate":0.003083},{"month":8,"riseRate":0.5,"avgChangeRate":0.00331},{"month":9,"riseRate":0.521739,"avgChangeRate":-0.006239},{"month":10,"riseRate":0.543478,"avgChangeRate":0.018718},{"month":11,"riseRate":0.717391,"avgChangeRate":0.032717},{"month":12,"riseRate":0.608696,"avgChangeRate":0.013778}],"exchange":"NYSE","name":"默沙东","nameEN":"Merck"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"默沙东,MRK,默沙东股票,默沙东股票老虎,默沙东股票老虎国际,默沙东行情,默沙东股票行情,默沙东股价,默沙东股市,默沙东股票价格,默沙东股票交易,默沙东股票购买,默沙东股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"默沙东(MRK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供默沙东(MRK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}